MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-9966
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1 ; volume:39 ; number:1 ; day:2 ; month:1 ; year:2020 ; pages:1-15 ; date:12.2020
Journal of experimental & clinical cancer research ; 39, Heft 1 (2.1.2020), 1-15, 12.2020
- Urheber
-
Vescarelli, Enrica
Gerini, Giulia
Megiorni, Francesca
Anastasiadou, Eleni
Pontecorvi, Paola
Solito, Luciana
De Vitis, Claudia
Camero, Simona
Marchetti, Claudia
Mancini, Rita
Benedetti Panici, Pierluigi
Dominici, Carlo
Romano, Ferdinando
Angeloni, Antonio
Marchese, Cinzia
Ceccarelli, Simona
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13046-019-1490-7
- URN
-
urn:nbn:de:101:1-2020041121590252329368
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:01 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Vescarelli, Enrica
- Gerini, Giulia
- Megiorni, Francesca
- Anastasiadou, Eleni
- Pontecorvi, Paola
- Solito, Luciana
- De Vitis, Claudia
- Camero, Simona
- Marchetti, Claudia
- Mancini, Rita
- Benedetti Panici, Pierluigi
- Dominici, Carlo
- Romano, Ferdinando
- Angeloni, Antonio
- Marchese, Cinzia
- Ceccarelli, Simona
- SpringerLink (Online service)
Ähnliche Objekte (12)
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
Combinations of ATR, Chk1 and Wee1 inhibitors with Olaparib are active in Olaparib resistant Brca1 proficient and deficient murine ovarian cells
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas
Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death
Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes Taxol-resistant cancer cells to Taxol
Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer
Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids
Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
Combinations of ATR, Chk1 and Wee1 inhibitors with Olaparib are active in Olaparib resistant Brca1 proficient and deficient murine ovarian cells
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas
Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death
Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes Taxol-resistant cancer cells to Taxol
Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer
Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids
Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer
Combinations of ATR, Chk1 and Wee1 inhibitors with Olaparib are active in Olaparib resistant Brca1 proficient and deficient murine ovarian cells
AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas
Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death
Warburg effect in chemosensitivity: Targeting lactate dehydrogenase-A re-sensitizes Taxol-resistant cancer cells to Taxol
Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer
Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids